The introduction of Acadia Healthcare Company’s ACHC new CEO to the financial community was well-received, according to Raymond James.
CEO Debra Osteen aims to release a comprehensive strategic plan in May, which should reflect the company’s capital deployment plans and the future of its UK portfolio, the sell-side firm said.
The Analyst
Raymond James’ John Ransom reiterated an Outperform rating and $40 price target for Acadia Healthcare.
The Thesis
During the earnings call, the behavioral health care provider said it closed nine UK facilities in 2018 and plans for some of these sites to serve higher acuity patients, Ransom said in a Monday note. The bed adds being targeted in 2019 will take place at existing facilities, he said.
The company guided to 2019 revenue of $3.15-$3.2 billion, adjusted EBITDA of $610-$630 million and adjusted EPS of $2.15-$2.30.
It expects 21.5 percent of the 2019 EBITDA to be generated in the first quarter
The biggest drivers in the year are likely to be the ramping of six de novos, rate increases in the U.S. and UK markets and an $8-$9-million improvement from the calendar and payroll taxes.
Acadia Healthcare remains best-positioned to leverage favorable industry trends according to Raymond James.
Price Action
Acadia Healthcare shares were down 2.89 percent at $29.53 at the time of publication Monday.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.